Monday January 27, 2020 20:55

Heathcare Press Release : 17 Sep 2019

Upjohn Thailands commitment to non-communicable diseases Heathcare—17 Sep 19

Upjohn Thailand announced its commitment and integrated strategy to improve patient health and relieve the burden of non-communicable diseases (NCDs) with trusted, quality medicines for every patient, everywhere. As Upjohn expands its capability in

Fiasp(R) Demonstrated Effective Overall Blood Sugar Reductions in People With Advanced Type 2 Diabetes Uncontrolled on Multiple Daily Injections (Basal-bolus Regimen) Heathcare—17 Sep 19

BAGSVAERD, Denmark--17 Sep--PRNewswire/InfoQuest

New data presented today at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed that, for people with advanced type 2 diabetes (≥10 years of diagnosis) not optimally controlled on their current basal-bolus regimen, Fiasp(R) (fast-acting insulin aspart) effectively reduced overall blood sugar levels (HbA1c), compared with conventional insulin aspart.1

"As type 2 diabetes progresses, people living with this condition might require a mealtime insulin to bring their post-meal blood sugar spikes down. Yet, some people might still struggle with blood sugar control even after the addition of a mealtime insulin," said Dr Wendy Lane, Mountain Diabetes and Endocrine Center, Asheville, North Carolina, USA, and study lead researcher. "With its ultra-fast profile of action, Fiasp(R) may be a suitable alternative option for people with type 2 diabetes struggling to manage their post-meal spikes."

In addition to effective overall blood sugar management, people treated with Fiasp(R) reported superior reductions in one-hour post-meal blood sugar increment, compared to those receiving conventional insulin aspart.1

"Research has shown that elevated blood sugar levels can lead to severe health implications, especially in those who have lived with